BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 13, 2026
Home
»
Topics
» Immuno-oncology, BioWorld Science
Immuno-oncology, BioWorld Science
RSS
Phase II trial of Avicine in prostate cancer announced
July 17, 1998
AltaRex initiates second phase II trial of OvaRex
July 16, 1998
Theragyn phase III testing will begin in U.K.
July 13, 1998
Regressin holds promise for a wide range of cancers, new data indicates
July 13, 1998
IL-4 fusion toxin shows potent antitumor activity in murine model of KS
July 10, 1998
NeoPharm scales up IL13-PE38QQR manufacturing
July 10, 1998
GOG will evaluate Avax Technologies' ovarian cancer vaccine in phase I/II study
July 6, 1998
Herceptin licensed to Roche for most markets
July 6, 1998
Phase II retreatment trial with Bexxar commences
June 30, 1998
Schering-Plough acquires Canadian rights to Ribi's melanoma theraccine
June 29, 1998
Previous
1
2
…
953
954
955
956
957
958
959
960
961
…
984
985
Next
RSS